Insights Series S2E7: Prof Benza about the rationale and design of a Phase II clinical trial in PAH

Raymond L. Benza, System Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board, speaks about the rationale and design of the Phase 2 clinical trial in PAH with drug candidate CS1, a controlled-release formulation of valproic acid. The video further provides commentary on the recently published research article in the medical journal Pulmonary Circulation about the design of the Phase II study with CS1.

Watch here >

English subtitles are available.

This video is episode 7 in the Insights Series season 2 and was recorded at the ESC Congress in August 2023.